Entest BioMedical, Inc. (OTCBB: ENTB) - New Waterville Research Client - Waterville Client News

Research Home

Search & Social

Deal Flow Media

Client Links

Stock Info

IR Web Report

Word Cloud

Monday

Nov222010

Entest BioMedical, Inc. (OTCBB: ENTB) - New Waterville Research Client

Entest BioMedical, Inc. (OTCBB: ENTB) is a biotechnology company focused on Veterinary Treatments that harness the animal’s reparative/ immunological mechanisms. Current market segments addressed by the Company’s treatments are:

Canine immuno-therapeutic cancer vaccines (dogs),
Expanded applications of immuno-therapeutic cancer vaccine for treating exotic species / zoo animals,
Development of Stem Cell related therapies for treating other veterinary maladies.

Entest also plans to acquire veterinary clinics for the marketing and distribution of its veterinary therapies. These clinics would provide immediate revenue and cash flow to fund development of the Company’s veterinary therapies. Entest believes it has the ability to self-fund R&D though internally generated cash flow.

Full Waterville Report @ ENTB Landing Page

Monday, November 22, 2010 at 2:13PM |

Email Article

Print Article

tagged

Antigens,

Cancer Vaccines,

Cancer treatment for dogs,

Canine Cancer,

Encapsulation device,

entb,

entest

Reader Comments

There are no comments for this journal entry. To create a new comment, use the form below.

Post a New Comment

Enter your information below to add a new comment.

My response is on my own website »

Author:

Author Email (optional):

Author URL (optional):

Post:

↓ | ↑

All HTML will be escaped. Hyperlinks will be created for URLs automatically.

Copyright © 2002 - 2011 Waterville Investment Research. All rights Reserved. Waterville Investment Research, and affiliates (WR), publishe reports providing information on selected companies. WR is not a registered investment advisor or broker-dealer. These reports are provided as an information service only, and the statements and opinions in these reports should not be construed as an offer or solicitation to buy or sell any security. WR accepts no liability for any loss arising from an investor's reliance on or use of these reports. An investment in any company is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. WR or an affiliate of WR has been/will be or may be compensated in Rule 144 stock of the Company for the publication and circulation of these reports. The maximum amount charged by WR is $75,000 in Rule 144 stock per report. WR intends to sell all or a portion of the of the Rule 144 stock in accordance with all securities laws, which prevents WR from selling stock for a period of six months to one year depending on the Bulletin Board and Pink Sheets regulations. WR, as a matter of internal policy, will not buy or sell shares of Company(s) stock in the open market. These reports contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. For further details concerning these risks and uncertainties, see the SEC filings of the individual Companies including the company's most recent annual and quarterly reports.